cjc-1295 + ipamorelin oral Peptide | Boise & Meridian, ID CJC 1295 & Ipamorelin Benefits,
Description
The company has two lead programs in its pipeline: 2B3-101 (now 2X-111 at Oncology Venture A/S) for recurrent malignant glioma has completed a Phase I/IIa clinical trial for brain metastases, and 2B3-201 (now ENX-201 at EnhanX Biopharm Inc.), which has completed a Phase I clinical trial in healthy volunteers for acute relapses of multiple sclerosis
Precisely tailoring molecular structure of doxorubicin prodrugs to enable stable nanoassembly, rapid activation, and potent antitumor effect
Biochim Biophys Acta 1757:115122
J., Zhou, M., Liu, Y
